Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Surgery Trials

Brighton, Michigan

Cancer surgery and procedure trials in Brighton, MI

42 cancer surgery and procedure studies are recruiting participants at sites in Brighton as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.

Call (888) 350-9284
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Brighton at a glance

  • 42 studies are recruiting at a site in Brighton.
  • By phase: Phase 2 (15), Phase 2/3 (1), Phase 3 (23), No phase (1), Observational (2). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (26), government (16).
  • By research area: Lung Cancer (13), Lymphoma (11), Breast Cancer (7), Prostate Cancer (6), Pancreatic Cancer (3), Melanoma (2).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Brighton

Basic details from each study's public record (the 30 most recently updated of 42). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton · University of Michigan - Brighton Center for Specialty Care
    Registry record
    NCT05564377 · updated
  2. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Registry record
    NCT07391774 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton · University of Michigan - Brighton Center for Specialty Care
    Registry record
    NCT06058377 · updated
  4. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT05334069 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Brighton, MI on ClinicalTrials.gov.

Lung cancer studies recruiting in Brighton

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · University of Michigan - Brighton Center for Specialty Care
    Registry record
    NCT06498635 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT04267848 · updated
  3. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Registry record
    NCT06096844 · updated
  4. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT04181060 · updated
  5. Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT03191149 · updated
  6. A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT07293247 · updated
  7. Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Registry record
    NCT07393555 · updated
  8. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • From 18 minutes
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT06031688 · updated
  9. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Registry record
    NCT06116682 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Brighton, MI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Brighton

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT03866382 · updated
  2. Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Registry record
    NCT06632977 · updated
  3. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Registry record
    NCT06931340 · updated
  4. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study sites
    Trinity Health Medical Center - Brighton · University of Michigan - Brighton Center for Specialty Care
    Registry record
    NCT05946213 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Brighton, MI on ClinicalTrials.gov.

Melanoma studies recruiting in Brighton

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT05136196 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Brighton, MI on ClinicalTrials.gov.

Lymphoma studies recruiting in Brighton

  1. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT03739814 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Registry record
    NCT06337318 · updated
  3. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT04269902 · updated
  4. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT04840602 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Registry record
    NCT05675410 · updated
  6. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT03150693 · updated
  7. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT05976763 · updated
  8. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    University of Michigan - Brighton Center for Specialty Care
    Registry record
    NCT07215910 · updated
  9. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    • Phase 3
    • Ages 65 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Registry record
    NCT07321652 · updated
  10. Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT05890352 · updated
  11. Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Registry record
    NCT07220187 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Brighton, MI on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Brighton

  1. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health IHA Medical Group Hematology Oncology - Brighton · Trinity Health Medical Center - Brighton
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Brighton, MI on ClinicalTrials.gov.

Ask about studies near Brighton

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Michigan

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.

Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 350-9284

or send a short form

How should we reach you?

Call